International Journal of Clinical Case Reports 2024, Vol.14, No.3, 132-143 http://medscipublisher.com/index.php/ijccr 133 combination therapies to overcome current limitations. This research contributes to the development of more effective peptide-based vaccines for oral cancer, offering new hope for patients battling this devastating disease. 2 Research Progress in Oral Cancer 2.1 Advances in understanding oral cancer biology Oral cancer, primarily squamous cell carcinoma, is a significant global health issue. Recent research has elucidated various molecular mechanisms underlying its pathogenesis. Tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) have been identified as key players in the development and progression of oral cancer. These antigens are recognized by the immune system, which can be harnessed for therapeutic purposes (Hirayama and Nishimura, 2016; Abd-Aziz and Poh, 2020). Additionally, the role of genetic mutations and epigenetic modifications in oral cancer has been extensively studied, providing insights into potential targets for novel therapies (Hirayama and Nishimura, 2016; Liu et al., 2021). 2.2 Diagnostic innovations for oral cancer Advancements in diagnostic technologies have significantly improved the early detection and management of oral cancer. Techniques such as liquid biopsy, which involves the analysis of circulating tumor DNA (ctDNA) and other biomarkers in bodily fluids, have shown promise in non-invasive cancer detection (Malonis et al., 2019). Imaging technologies, including advanced MRI and PET scans, have enhanced the accuracy of tumor localization and staging (Liu et al., 2021). Moreover, the development of molecular diagnostic tools, such as next-generation sequencing (NGS), has enabled the identification of specific genetic alterations associated with oral cancer, facilitating personalized treatment approaches (Hirayama and Nishimura, 2016; Tardón et al., 2019; Hamley, 2022). 2.3 Current therapeutic approaches for oral cancer The treatment landscape for oral cancer includes surgery, radiation therapy, and chemotherapy. However, these conventional therapies often come with significant side effects and limited efficacy in advanced stages. Immunotherapy has emerged as a promising alternative, with immune checkpoint inhibitors showing clinical benefits in some patients (Hirayama and Nishimura, 2016; Tardón et al., 2019). Additionally, targeted therapies that inhibit specific molecular pathways involved in tumor growth and metastasis are being explored. Combination therapies, which integrate traditional treatments with novel agents, are also under investigation to enhance therapeutic outcomes (Bezu et al., 2018; Liu et al., 2021). 2.4 Research on vaccine development for oral cancer Peptide-based vaccines represent a novel and promising approach in the fight against oral cancer. These vaccines are designed to elicit robust immune responses by targeting TAAs or TSAs specific to oral cancer cells (Abd-Aziz and Poh, 2020; Hirayama and Nishimura, 2016). The development of personalized peptide-based vaccines, which are tailored to the unique antigenic profile of an individual's tumor, has shown potential in enhancing antitumor immunity (Figure 1) (Hirayama and Nishimura, 2016; Bezu et al., 2018). Clinical trials have demonstrated that peptide-based vaccines can induce specific T-cell responses, although their efficacy varies among patients . To improve the clinical success of these vaccines, researchers are investigating the use of adjuvants and delivery systems that enhance immune activation and target antigen presentation (Malonis et al., 2019; Zamani et al., 2020). Combination therapies that integrate peptide-based vaccines with immune checkpoint inhibitors or other immunomodulatory agents are also being explored to overcome the immunosuppressive tumor microenvironment and improve therapeutic outcomes (Hirayama and Nishimura, 2016; Bezu et al., 2018; Malonis et al., 2019). Significant progress has been made in understanding the biology of oral cancer, developing advanced diagnostic tools, and exploring innovative therapeutic approaches. Peptide-based vaccines hold substantial promise as a targeted and personalized treatment strategy, with ongoing research focused on optimizing their efficacy and clinical application (Hirayama and Nishimura, 2016; Bezu et al., 2018; Tardón et al., 2019; Abd-Aziz and Poh, 2020; Liu et al., 2021).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==